Rimouski, QC, Canada—innoVactiv Inc. says it has “statistically significant results” from a new human clinical trial on its carb/starch control ingredient (InSea2). The study tested its ability to lower glucose and insulin levels in the blood after eating. Researchers from the Institute of Nutraceuticals and Functional Foods of Laval University in Quebec determined that taking 500 mg of the ingredient resulted in a 44% drop in glucose levels after eating white bread. In addition, the ingredient caused a 22% reduction in insulin production. These results, based off a 23-person study, will be presented at the Experimental Biology meeting in Anaheim, CA (April 24–28, 2010).
Published in WholeFoods Magazine, March 2010